In this article, we break down the Top 5 AI-Powered Healthcare Stocks That Can Make You Rich. For investors looking for the complete list, you can explore our full report on the Top 10 AI-Powered Healthcare Stocks That Can Make You Rich.
5. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ranks fifth among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and this is one of the more important biotechnology names on the list because it combines an established commercial drug portfolio with a continuing push into complex disease areas. Trading at $632.90, with the stock up 2.06%, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is backed by 72 hedge fund holders, showing that institutional investors continue to follow the company despite rising competition in some of its most important markets. For investors searching for healthcare stocks to buy, biotech stocks, pharmaceutical stocks, drug development stocks, immunology stocks, and AI-powered healthcare stocks with long-term upside, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a serious name because it is not simply chasing one product cycle. It has a broader research and development platform, a known commercial portfolio, and a pipeline that continues to attract regulatory attention.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration and the European Medicines Agency accepted regulatory applications for cemdisiran, a treatment candidate for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. That sounds highly technical, but the investment story is straightforward: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trying to expand further into serious immune-mediated diseases where treatment options remain important and where effective therapies can create meaningful commercial value. Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder that can cause muscle weakness and fatigue, making it a disease area where improved treatment convenience and durability can matter a lot for patients and physicians.
The FDA granted Priority Review for the cemdisiran new drug application, with a target action date set in November 2026 after the use of a priority review voucher. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) also expects a European Commission decision in the second half of 2027. The filings are backed by data from the Phase 3 NIMBLE trial, which evaluated subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic generalized myasthenia gravis. The dosing schedule is a key detail because convenience matters in chronic disease treatment. A medicine that can be administered every 12 weeks may appeal to patients and clinicians if the safety and efficacy profile is compelling enough. For long-term investors, regulatory acceptance itself is not a final approval, but it is a meaningful step that keeps Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s pipeline story active.
At the same time, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is also dealing with competitive pressure. On the same day, RBC Capital maintained a Sector Perform rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), but the firm described AbbVie’s acquisition of Apogee Therapeutics as a “net negative” for the company. RBC Capital argued that the deal adds fuel to a potential next-generation competitor to Dupixent, one of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s most important products. The concern is that AbbVie brings commercial expertise and long-standing dermatology market relationships behind Apogee’s IL-13 antibody program. In simple market terms, a stronger competitor with a powerful commercial partner can pressure investor sentiment even if the current business remains healthy.
The trivia here is that biotechnology investing is often not just about whether a company has good drugs. It is also about timing, regulatory pathways, patent life, competition, payer coverage, physician adoption, and how quickly a rival can build a better or more convenient therapy. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a well-known brand lineup that includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara, which gives the company more depth than many smaller biotech names. Still, the market will continue watching whether Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) can protect its existing franchises while building new growth drivers from its pipeline.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. For investors looking for best healthcare stocks, AI-powered healthcare stocks, biotech stocks to buy, immunology stocks, rare disease treatment stocks, and long-term pharmaceutical stocks, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) remains a high-quality but closely watched name. Its cemdisiran regulatory progress gives investors a fresh pipeline catalyst, while the competitive noise around Dupixent serves as a reminder that even the strongest healthcare companies must keep innovating to defend their market position.
Click next to see the following stock...
